Blood Pressure Lowering in Patients With Cerebrovascular Disease: Results of the Randomized Post-stroke Antihypertensive Treatment Study (PATS)

1998 ◽  
Vol 31 (2) ◽  
pp. 211A ◽  
Author(s):  
L Liu
Keyword(s):  
Blood Pressure ◽  
Cerebrovascular Disease ◽  
Antihypertensive Treatment ◽  
Blood Pressure Lowering ◽  
Post Stroke ◽  
Pressure Lowering

Perindopril-based blood pressure lowering in individuals with cerebrovascular disease

2004 ◽  
Vol 22 (3) ◽  
pp. 653-659 ◽  
Author(s):  
Anthony Rodgers ◽  
Neil Chapman ◽  
Mark Woodward ◽  
Li-Sheng Liu ◽  
Sam Colman ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cerebrovascular Disease ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

scholarly journals Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial

Circulation ◽  
2016 ◽  
Vol 134 (12) ◽  
pp. 847-857 ◽  
Author(s):  
Michel Azizi ◽  
Helena Pereira ◽  
Idir Hamdidouche ◽  
Philippe Gosse ◽  
Matthieu Monge ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Treatment ◽  
Renal Denervation ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

scholarly journals Blood Pressure Lowering for the Prevention of Stroke Recurrence

2010 ◽  
Vol 6 (1) ◽  
pp. 37 ◽  
Author(s):  
Zengwu Wang ◽  
Tom Richart ◽  
Yu Jin ◽  
Jan A Staessen ◽  
Lisheng Liu ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cerebrovascular Disease ◽  
Meta Analysis ◽  
Blood Pressure Reduction ◽  
Previous History ◽  
Stroke Recurrence ◽  
Significant Heterogeneity ◽  
Pressure Reduction ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

Stroke is the second most common cause of mortality worldwide. It is the complication of hypertension that has the most direct link to blood pressure. Hypertension affects nearly 30% of the world’s population. In addition to hypertension, a previous history of cerebrovascular disease is a powerful predictor of stroke recurrence. In a meta-analysis of 10 trials of patients with previous cerebrovascular disease, blood-pressure-lowering treatment reduced systolic blood pressure (ΔSBP) by 5.1mmHg and the risk of stroke recurrence by 22% (p=0.0007) compared with no treatment or placebo. In four trials involving diuretics as a component of therapy (ΔSBP 9.6mmHg), the pooled reduction of stroke recurrence averaged 37% (p<0.0001), whereas it was only 7% in six trials of renin system inhibitors (ΔSBP 4.0mmHg). In metaregression analysis, the weighted correlation co-efficient between the odds for stroke recurrence and the blood pressure reduction was -0.57 (p=0.067). The significant heterogeneity (p<0.0001) between diuretics and renin system inhibitors in the prevention of stroke recurrence might be explained by the greater blood pressure reduction of treatments including diuretics. Our results do not support the use of renin system inhibitors for the prevention of stroke recurrence.

Abstract WP347: Early Achievement of Blood Pressure Lowering on Hematoma Growth in Hyperacute Intracerebral Hemorrhage: the SAMURAI-ICH Study

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Yoshitaka Yamaguchi ◽  
Masatoshi Koga ◽  
Kenichi Todo ◽  
Shoichiro Sato ◽  
Hiroshi Yamagami ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Intracerebral Hemorrhage ◽  
Antihypertensive Treatment ◽  
Blood Pressure Lowering ◽  
Acute Hypertension ◽  
Negatively Associated ◽  
Significant Difference ◽  
Pressure Lowering ◽  
Hematoma Growth ◽  
Multicenter Prospective Observational Study

Background: Little has been investigated about associations between timing of blood pressure lowering and clinical outcome of intracerebral hemorrhage (ICH). Methods: The Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI)-ICH Study is a multicenter, prospective, observational study investigating the safety and feasibility of early (within 3 hours from symptom onset) systolic blood pressure (SBP) reduction to less than 160 mmHg with intravenous nicardipine for acute hypertension in patients with spontaneous ICH. We retrospectively examined the relationship between time from onset, CT imaging, and initiation of antihypertensive treatment to target SBP achievement and hematoma growth in ICH patients. Hematoma growth was defined as an absolute growth of ≥ 6 ml from baseline to second imaging at 24 (±6) hours after the initiation of antihypertensive treatment. Results: Among 211 patients (81 women (38.4%), mean age 66 years), mean baseline hematoma volume was 13 ml and hematoma growth was seen in 36 (17.1%) patients. Time from image to target SBP and time from treatment to target SBP were significantly shorter in patients without hematoma growth than those with ( P = 0.043 and P = 0.032, respectively), whereas there was not significant difference in time from onset to target SBP between the two groups ( P = 0.177). Lower quartiles of time from image to target SBP and time from treatment to target SBP had lower incidences of hematoma growth (P trend = 0.023 and 0.037, respectively, Cochran-Armitage test), whereas there was not significant trend in time from onset to target SBP ( P = 0.074). The lowest quartile of time from image to target SBP was negatively associated with hematoma growth on multivariate logistic regression (odds ratio 0.182, 95% confidential interval 0.038-0.867, P = 0.032). Conclusions: Early achievement to target SBP <160 mmHg was negatively associated with hematoma growth in ICH patients.

scholarly journals Intensive blood-pressure lowering in patients with acute cerebral hemorrhage

CJEM ◽  
2017 ◽  
Vol 20 (2) ◽  
pp. 256-259 ◽  
Author(s):  
Sufyan Alrahbi ◽  
Rashid Alaraimi ◽  
Abdalla Alzaabi ◽  
Sophie Gosselin
Keyword(s):  
Blood Pressure ◽  
Cerebral Hemorrhage ◽  
Antihypertensive Treatment ◽  
Therapeutic Benefit ◽  
Blood Pressure Lowering ◽  
Pressure Lowering ◽  
Acute Intracerebral Hemorrhage ◽  
Better Than ◽  
Intensive Blood Pressure

Clinical questionIs intensive blood pressure (BP) treatment (systolic BP target 110-139 mm Hg) better than standard antihypertensive treatment (systolic BP target 140-179 mm Hg) in reducing mortality and disability in patients with acute intracerebral hemorrhage (ICH)?Article chosenQureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016;375(11):1033-43.ObjectiveTo determine the therapeutic benefit of intensive BP treatment compared to standard BP treatment in reducing death and disability after 3 months of follow-up among patients with ICH treated within 4.5 hours from onset of symptoms.

Sign in / Sign up

Export Citation Format

Share Document